{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["furmonertinib"]],"indication":"advanced or metastatic NSCLC with EGFR/HER2 mutations","name":"NCT05364073","nct_id":"NCT05364073","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05364073. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Experimental: Previously treated patients with advanced or metastatic NSCLC with activating EGFR or HER2 mutations","label":"Stage 1 Dose Escalation and Backfill","type":"EXPERIMENTAL"},{"description":"Previously Treated NSCLC Patients with EGFR Exon 20 Insertion Mutations","label":"Stage 2 Expansion Cohort 1","type":"EXPERIMENTAL"},{"description":"Previously treated NSCLC Patients with HER2 Exon 20 Insertion Mutations","label":"Stage 2 Expansion Cohort 2","type":"EXPERIMENTAL"},{"description":"Previously treated NSCLC Patients with EGFR Activating Mutations, who are not eligible for Cohorts 1 and 4","label":"Stage 2 Expansion Cohort 3","type":"EXPERIMENTAL"},{"description":"Untreated or Previously treated EGFR TKI Naïve NSCLC Patients with EGFR Uncommon Mutations, excluding EGFR exon 20 insertion mutations","label":"Stage 2 Expansion Cohort 4","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","HER2 Exon 20 Mutations","EGFR Exon 20 Mutations","EGFR Uncommon Mutations, Including G719X and S768I"],"enrollment":{"count":160,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Furmonertinib","otherNames":["AST2818"],"type":"DRUG"},{"name":"Furmonertinib","otherNames":["AST2818"],"type":"DRUG"},{"name":"Furmonertinib","otherNames":["AST2818"],"type":"DRUG"},{"name":"Furmonertinib","otherNames":["AST2818"],"type":"DRUG"},{"name":"Furmonertinib","otherNames":["AST2818"],"type":"DRUG"}],"last_update":"2026-03-13","lead_sponsor":"ArriVent BioPharma, Inc.","official_title":"A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-06-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Stage 1: Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of Furmonertinib","timeFrame":"Up to 36 months after first dose"},{"measure":"Stage 2: Overall Response Rate (ORR)","timeFrame":"Up to 36 months after first dose"}],"references":[],"start_date":{"date":"2022-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","url":"https://clinicaltrials.gov/study/NCT05364073"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05364073"}